Explore more publications!
Harrisburg Wellness Reporter
Got News to Share?

Harrisburg Wellness Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Harrisburg Wellness Reporter.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 9, 2025

A.D.A.M. Innovations Announces the Launch of ALUNAÉ
December 9, 2025

A.D.A.M. Innovations Announces the Launch of ALUNAÉ

Indeterminate GlobeNewswire
STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico
December 9, 2025

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico

Indeterminate GlobeNewswire
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
December 9, 2025

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Indeterminate GlobeNewswire
Inspira Technologies Granted Patent in Japan for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use
December 9, 2025

Inspira Technologies Granted Patent in Japan for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use

Indeterminate GlobeNewswire
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
December 9, 2025

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Indeterminate GlobeNewswire
Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
December 9, 2025

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Indeterminate GlobeNewswire
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
December 9, 2025

LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices

Indeterminate GlobeNewswire
Codetta Bio™ Expands Global Commercial Leadership to Accelerate Worldwide Adoption of the Concerto™ System
December 9, 2025

Codetta Bio™ Expands Global Commercial Leadership to Accelerate Worldwide Adoption of the Concerto™ System

Indeterminate GlobeNewswire
AnswersNow Expands Virtual Autism Therapy and Caregiver Training Services to Colorado
December 9, 2025

AnswersNow Expands Virtual Autism Therapy and Caregiver Training Services to Colorado

Indeterminate GlobeNewswire
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
December 9, 2025

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Indeterminate GlobeNewswire
BioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision
December 9, 2025

BioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision

Indeterminate GlobeNewswire
23andMe Research Institute Appoints John McLeod General Counsel and Chief Risk Officer
December 9, 2025

23andMe Research Institute Appoints John McLeod General Counsel and Chief Risk Officer

Indeterminate GlobeNewswire
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
December 9, 2025

Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution

Indeterminate GlobeNewswire
AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative Medical Product Designation in Japan
December 9, 2025

AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative Medical Product Designation in Japan

Indeterminate GlobeNewswire
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
December 9, 2025

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Indeterminate GlobeNewswire
Cronos to enter the Netherlands with acquisition of Europe’s largest adult-use cannabis company
December 9, 2025

Cronos to enter the Netherlands with acquisition of Europe’s largest adult-use cannabis company

Indeterminate GlobeNewswire
Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs
December 9, 2025

Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs

Indeterminate GlobeNewswire
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
December 9, 2025

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Indeterminate GlobeNewswire
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
December 9, 2025

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Indeterminate GlobeNewswire
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
December 9, 2025

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions